Implantica AG Stock

Equities

IMP A SDB

SE0014855029

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Stockholm 11:29:33 2024-04-19 am EDT 5-day change 1st Jan Change
29 SEK +1.22% Intraday chart for Implantica AG -2.36% +21.34%

Financials

Sales 2023 1.41M 1.5M 16.38M Sales 2024 * 3.6M 3.83M 41.89M Capitalization 705M 752M 8.21B
Net income 2023 -23M -24.5M -268M Net income 2024 * -36M -38.35M -419M EV / Sales 2023 369 x
Net cash position 2023 87.92M 93.66M 1.02B Net cash position 2024 * 50.95M 54.27M 593M EV / Sales 2024 * 182 x
P/E ratio 2023
-6.31 x
P/E ratio 2024 *
-3.95 x
Employees -
Yield 2023 *
-
Yield 2024 *
-
Free-Float 4.86%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.22%
1 week-2.36%
Current month-7.35%
3 months+5.07%
6 months+62.92%
Current year+21.34%
More quotes
1 week
28.35
Extreme 28.35
30.75
1 month
27.25
Extreme 27.25
32.70
Current year
23.80
Extreme 23.8
33.00
1 year
15.40
Extreme 15.4
33.00
3 years
15.40
Extreme 15.4
136.80
5 years
15.40
Extreme 15.4
178.90
10 years
15.40
Extreme 15.4
178.90
More quotes
Managers TitleAgeSince
Chief Executive Officer 70 14-12-31
Director of Finance/CFO 46 19-12-31
Director/Board Member 67 19-12-31
Members of the board TitleAgeSince
Director/Board Member 69 19-12-31
Chairman 65 19-12-31
Director/Board Member 60 19-12-31
More insiders
Date Price Change Volume
24-04-19 29 +1.22% 11,452
24-04-18 28.65 -0.87% 15,501
24-04-17 28.9 -2.36% 16,904
24-04-16 29.6 -1.00% 17,945
24-04-15 29.9 +0.67% 45,726

Delayed Quote Nasdaq Stockholm, April 19, 2024 at 11:29 am EDT

More quotes
Implantica AG is Lichtenstein-based medical technology Company, whose mission is to provide effective treatment for serious health conditions and to improve patients' life through the use of advanced technologies in the human body, ultimately aiming to reduce costs and increase efficiency in the healthcare System. The therapies developed by Implantica are based on implants that are inserted into the patient's body and remain in the body permanently or semi-permanently to replace bodily functions and/or treat diseases. The Company focuses on the discovery, development and prospective commercialization of medical products and implants that are intended for use in different treatment fields like in the area of gastrointestinal surgery and urology. The Company's lead product is RefluxStop, a passive, implant to prevent gastroesophageal reflux disease (GERD).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
2.492 EUR
Average target price
3.834 EUR
Spread / Average Target
+53.86%
Consensus
  1. Stock Market
  2. Equities
  3. IMP A SDB Stock